Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (9)

2024

  1. Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study

    Diseases, Vol. 12, Núm. 10

2023

  1. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  2. Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients

    International Journal of Molecular Sciences, Vol. 24, Núm. 14

  3. Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response

    Cancers, Vol. 15, Núm. 3

2022

  1. Borderline breast lesions: diagnostic classification and management

    Revista de Senologia y Patologia Mamaria, Vol. 35, Núm. 1, pp. 16-22

2021

  1. Delineating the neurological phenotype in children with defects in the ECHS1 or HIBCH gene

    Journal of Inherited Metabolic Disease, Vol. 44, Núm. 2, pp. 401-414

  2. Predictive and prognostic value of total tumor load in sentinel lymph nodes in breast cancer patients after neoadjuvant treatment using one-step nucleic acid amplification: the NEOVATTL study

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1377-1385

2020

  1. Low prevalence of HER2-positive breast carcinomas among screening detected breast cancers

    Cancers, Vol. 12, Núm. 6, pp. 1-16

2014

  1. VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer

    Endocrine-Related Cancer, Vol. 21, Núm. 4, pp. 587-599